Janux Therapeutics (NASDAQ: JANX) net income
Janux Therapeutics reported a net loss of $113.6m for fiscal 2025; in fiscal 2024 it reported a net loss of $69.0m. Earnings per share were −$1.83.
Janux Therapeutics's best year of the last 6 was fiscal 2020. It reported a loss in 6 of those 6 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$113.6m | — | −1,136.3% | −$1.83 |
| 2024 | −$69.0m | — | −651.6% | −$1.28 |
| 2023 | −$58.3m | — | −721.2% | −$1.32 |
| 2022 | −$63.1m | — | −732.2% | −$1.52 |
| 2021 | −$32.7m | — | −898.3% | −$1.39 |
| 2020 | −$6.8m | — | — | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Janux Therapeutics net income compared with its sector
By net income for its latest fiscal year, Janux Therapeutics ranks 348th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Janux Therapeutics, −1,136.3%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 346th | Taysha Gene Therapies | −$109.0m | −1,115.3% |
| 347th | Rapport Therapeutics | −$111.5m | — |
| 348th | Janux Therapeutics | −$113.6m | −1,136.3% |
| 349th | IDEAYA Biosciences | −$113.7m | −52.0% |
| 350th | MeiraGTx | −$114.2m | −140.3% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Janux Therapeutics
- How much did Janux Therapeutics earn in fiscal 2025?
- Janux Therapeutics reported a net loss of $113.6m for fiscal 2025. In fiscal 2024 it reported a net loss of $69.0m.
- What are the earnings per share of Janux Therapeutics?
- They were −$1.83 in fiscal 2025, compared with −$1.28 in fiscal 2024.
- Where does Janux Therapeutics rank in its sector by net income?
- It ranks 348th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Janux Therapeutics come from?
- From the annual report (Form 10-K) that Janux Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Janux Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Janux Therapeutics: the Janux Therapeutics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.